Pramoxine: Difference between revisions

Pramoxine
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a682429
Routes of; administration	Topical, rectal, Vaginal
ATC code	D04AB07 (WHO) C05AD07 (WHO);
Legal status
Legal status	CA: OTC ; UK: POM (Prescription only) ; OTC/POM;
Identifiers
	IUPAC name 4-[3-(4-butoxyphenoxy)propyl]morpholine;
CAS Number	140-65-8 637-58-1;
PubChem CID	4886;
ChemSpider	4717 ;
UNII	068X84E056;
ChEBI	CHEBI:8357 ;
ChEMBL	ChEMBL1198 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H27NO3
Molar mass	293.401 g/mol
3D model (JSmol)	Interactive image;
	SMILES O(c2ccc(OCCCN1CCOCC1)cc2)CCCC;
	InChI InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3 ; Key:DQKXQSGTHWVTAD-UHFFFAOYSA-N ;
(what is this?) (verify)

Pramoxine
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

← Older edit Newer edit →

VisualWikitext

Revision as of 13:16, 28 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Pramoxine is a local anesthetic that is FDA approved for the treatment of for the temporary relief of itching associated with minor skin irritations. Common adverse reactions include contact dermatitis, eczema.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

For the temporary relief of itching associated with minor skin irritations

Dosing information

To open, squeeze cap tightly and turn pump counter-clockwise.
Adults and children 2 years of age and older:

apply to affected area not more than 3 to 4 times daily.
Children under 2 years of age: consult a doctor.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pramoxine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pramoxine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Pramoxine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pramoxine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pramoxine in pediatric patients.

Contraindications

There is limited information regarding Pramoxine Contraindications in the drug label.

Warnings

For external use only

When using this product

avoid contact with the eyes.

Stop use and ask a doctor if

condition worsens

symptoms persist for more than 7 days or clear up and occur again within a few days.

Caution -- Do not use in the eyes or nose. Not for prolonged use. Do not apply to large areas of the body. If redness, irritation, swelling, or pain persists or increases, discontinue use unless directed by a physician.

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Pramoxine in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Pramoxine in the drug label.

Drug Interactions

There is limited information regarding Pramoxine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pramoxine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pramoxine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Pramoxine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Pramoxine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Pramoxine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Pramoxine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pramoxine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pramoxine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pramoxine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pramoxine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pramoxine in patients who are immunocompromised.

Administration and Monitoring

Administration

Topical

Monitoring

There is limited information regarding Monitoring of Pramoxine in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Pramoxine in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Pramoxine in the drug label.

Pharmacology

Mechanism of Action

There is limited information regarding Pramoxine Mechanism of Action in the drug label.

Structure

There is limited information regarding Pramoxine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Pramoxine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Pramoxine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Pramoxine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Pramoxine in the drug label.

How Supplied

There is limited information regarding Pramoxine How Supplied in the drug label.

Storage

There is limited information regarding Pramoxine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Pramoxine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Pramoxine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Pramoxine in the drug label.

Precautions with Alcohol

Alcohol-Pramoxine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Curasore
Prax
Proctofoam-NS
Tronolane
Sarna Sensitive
Proctofoam
PramoxGel

Look-Alike Drug Names

There is limited information regarding Pramoxine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Label Page=Pramoxine
 |Label Name=Pramoxine03.png

}}

{{#subobject:

 |Label Page=Pramoxine
 |Label Name=Pramoxine04.png

}}

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
 |authorTag={{AV}}
-<!--Overview-->
 |genericName=pramoxine hydrochloride
+|aOrAn=a
-|aOrAn=
-a
 |drugClass=local anesthetic
+|indicationType=treatment
 |indication=for the temporary relief of itching associated with minor skin irritations
-|hasBlackBoxWarning=
 |adverseReactions=[[contact dermatitis]], [[eczema]]
@@ Line 28: / Line 11: @@
 <!--Black Box Warning-->
+|blackBoxWarningTitle=Title
-|blackBoxWarningTitle=
+|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
-Title
-|blackBoxWarningBody=
-<i><span style="color:#FF0000;">ConditionName: </span></i>
 * Content
@@ Line 40: / Line 19: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
+|fdaLIADAdult=*For the temporary relief of itching associated with minor skin irritations
-|fdaLIADAdult=
-*For the temporary relief of itching associated with minor skin irritations
 =====Dosing information=====
 *To open, squeeze cap tightly and turn pump counter-clockwise.
@@ Line 52: / Line 29: @@
 <!--Guideline-Supported Use (Adult)-->
+|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-|offLabelAdultGuideSupport=
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Non–Guideline-Supported Use (Adult)-->
+|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
-|offLabelAdultNoGuideSupport=
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 <!--Pediatric Indications and Dosage-->
 <!--FDA-Labeled Indications and Dosage (Pediatric)-->
+|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
-|fdaLIADPed=
-There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Off-Label Use and Dosage (Pediatric)-->
 <!--Guideline-Supported Use (Pediatric)-->
+|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-|offLabelPedGuideSupport=
-There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Non–Guideline-Supported Use (Pediatric)-->
+|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
-|offLabelPedNoGuideSupport=
-There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 <!--Contraindications-->
+|contraindications=<!--Warnings-->
-|contraindications=
+|warnings=* For external use only
-<!--Warnings-->
-|warnings=
-* For external use only
 *When using this product
@@ Line 122: / Line 67: @@
 *If swallowed, get medical help or contact a Poison Control Center right away.<!--Adverse Reactions-->
 <!--Clinical Trials Experience-->
+|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
-|clinicalTrials=
-There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 <!--Postmarketing Experience-->
+|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
-|postmarketing=
-There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 <!--Drug Interactions-->
+|drugInteractions=<!--Use in Specific Populations-->
-|drugInteractions=
+|useInPregnancyFDA=* '''Pregnancy Category'''
+|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
-<!--Use in Specific Populations-->
-|useInPregnancyFDA=
-* '''Pregnancy Category'''
-|useInPregnancyAUS=
-* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
+|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
-|useInLaborDelivery=
+|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
-There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
+|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
+|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
-|useInNursing=
+|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
-There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
+|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
+|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
-|useInPed=
+|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
-There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
+|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
+|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
-|useInGeri=
-There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
-|useInGender=
-There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
-|useInRace=
-There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
-|useInRenalImpair=
-There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
-|useInHepaticImpair=
-There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
-|useInReproPotential=
-There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
-|useInImmunocomp=
-There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 <!--Administration and Monitoring-->
+|administration=* Topical
-|administration=
+|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
-* Topical
-|monitoring=
-There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 <!--IV Compatibility-->
+|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
-|IVCompat=
-There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 <!--Overdosage-->
+|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
-|overdose=
-There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 <!--Pharmacology-->
 <!--Drug box 2-->
 |drugBox={{Drugbox
 | Verifiedfields = changed
@@ Line 267: / Line 166: @@
 <!--Mechanism of Action-->
+|mechAction=<!--Structure-->
-|mechAction=
+|structure=<!--Pharmacodynamics-->
+|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
-<!--Structure-->
-|structure=
-<!--Pharmacodynamics-->
-|PD=
-There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 <!--Pharmacokinetics-->
+|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
-|PK=
-There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 <!--Nonclinical Toxicology-->
+|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
-|nonClinToxic=
-There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 <!--Clinical Studies-->
+|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
-|clinicalStudies=
-There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 <!--How Supplied-->
+|howSupplied=<!--Patient Counseling Information-->
-|howSupplied=
+|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
-<!--Patient Counseling Information-->
-|fdaPatientInfo=
-There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 <!--Precautions with Alcohol-->
+|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
-|alcohol=
-* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 <!--Brand Names-->
+|brandNames=*Curasore
-|brandNames=
-*Curasore
 *Prax
 *Proctofoam-NS
@@ Line 331: / Line 196: @@
 <!--Look-Alike Drug Names-->
+|lookAlike=<!--Drug Shortage Status-->
-|lookAlike=
-<!--Drug Shortage Status-->
 |drugShortage=
 }}
 <!--Pill Image-->

Pramoxine: Difference between revisions

Revision as of 13:16, 28 April 2015

Disclaimer

Overview

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Dosing information

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Non–Guideline-Supported Use

Contraindications

Warnings

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Drug Interactions

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatic Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Administration and Monitoring

Administration

Monitoring

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Nonclinical Toxicology

Clinical Studies

How Supplied

Storage

Images

Drug Images

Package and Label Display Panel

Patient Counseling Information

Precautions with Alcohol

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

Navigation menu

Search